iSOFT Hosts Forum to Discuss Future Role of eClinical Trial Technologies

iSOFTiSOFT recently hosted the eClinical Forum to discuss how existing and emerging healthcare environments impact on clinical trials, and the future role of eClinical trial technologies.

The eClinical Forum was formed in 2000 by Pharmaceutical industry representatives with a vision to create a non-commercial and informal environment in which to network with peers, share ideas and experiences, and to shape the future of the clinical research environment.

The meeting was held at iSOFT's headquarters and was opened by iSOFT chief executive Andrea Fiumicelli who explained that despite the enormous progresses made, much needed to be done to improve the delivery of healthcare, and in particular improve safety through better use of information systems.

The clinical trial process was a key focus of the session. Identifying eligible patients for clinical trials is a constant challenge, and 58 per cent of clinical trials fail to achieve their recruitment targets. Dr Joerg Kraenzlein, director of life science at iSOFT described a system which is being developed to help investigators and pharmaceuticals companies conduct clinical trials more easily. "We want to build a network for physicians to collaborate, foster the use of personalised medicine and the production of clinical trials helping to speed up the process," he explained.

In the iSOFT system under development, patient records are de-identified and medical terms extracted to create the AccelCDB (Clinical Database). The investigator can then use the AccelFind web base application to identify suitable patients for the trial by defining the inclusion and exclusion criteria.

"It just takes 5 to 10 seconds to screen 10,000 medical records, whereas with a manual process a physician has to work for weeks," Dr Kraenzlein said.

The forum agreed that there is an urgent need for an integrated solution for research activities to increase efficiency while maintaining a high level of quality. This will help shorten the clinical trial process and ultimately assist in bringing drugs to market in a more timely way.

Related news articles:

About iSOFT a CSC company
Headquartered in Banbury, UK, iSOFT is one of the world's largest healthcare IT companies serving 13,000 healthcare providers in over 40 countries across five continents. Its software product portfolio is one of the most extensive available, covering every aspect of healthcare delivery and planning. These include interoperable e-health solutions that build on existing systems to maximize current investments.

iSOFT's business is driven by the collective talent, experience and commitment of over 3,000 specialists in 19 countries. Through a global network of subsidiaries and extensive partner network, iSOFT also has substantial experience of national healthcare sectors and expert knowledge of local market needs.

iSOFT is a CSC Company.

Most Popular Now

AI Tool Helps Predict Relapse of Pediatr…

Artificial intelligence (AI) shows tremendous promise for analyzing vast medical imaging datasets and identifying patterns that may be missed by human observers. AI-assisted interpretation of brain scans may help improve...

Infectious Disease Surveillance Platform…

The Biothreats Emergence, Analysis and Communications Network (BEACON) leverages advanced artificial intelligence (AI), large language models (LLMs) and a network of globally based experts to rapidly collect, analyze, and disseminate...

Children's Health Ireland to Transf…

Healthcare teams responsible for paediatric care in Ireland are to save significant time in accessing important diagnostic imaging and reports, with the help of a new agreement with medical imaging...

NHS, Councils, and Housing could Share N…

A new technology partnership formally announced, could help NHS, local government, and housing organisations collaborate to create an unprecedented understanding of the risks and needs of people in their care...

AI-Powered Analysis of Stent Healing

Each year, more than three million people worldwide are treated with stents to open blocked blood vessels caused by heart disease. However, monitoring the healing process after implantation remains a...

Right Patient, Right Dose, Right Time

While artificial intelligence (AI) has shown promising potential, much of its use has remained theoretical or retrospective. Turning its potential into real-world healthcare outcomes, researchers at the Yong Loo Lin...

AXREM and BHTA Name Highland as 'Fu…

Hosted by trade associations AXREM and the British Healthcare Trades Association (BHTA), 'The Future of MedTech - Innovating for Tomorrow', will allow delegates to engage with speakers from the government...

AI could Help Improve Early Detection of…

A new study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center suggests that artificial intelligence (AI) could help detect interval breast cancers - those that develop between...

Building Trust in Artificial Intelligenc…

A new review, published in the peer-reviewed journal AI in Precision Oncology, explores the multifaceted reasons behind the skepticism surrounding artificial intelligence (AI) technologies in healthcare and advocates for approaches...

SALSA: A New AI Tool for the Automated a…

Investigators of the Vall d'Hebron Institute of Oncology's (VHIO) Radiomics Group, led by Raquel Perez-Lopez, have developed SALSA (System for Automatic Liver tumor Segmentation And detection), a fully automated deep...

Siemens Healthineers infection Control S…

Klinikum Region Hannover (KRH) has commissioned Siemens Healthineers to install infection control system (ICS) at the Klinikum Siloah hospital. The ICS aims to effectively tackle nosocomial infections and increase patient...

Call for Papers: AI Applications in Biom…

JMIR Biomedical Engineering is inviting submissions for a new section titled "AI Applications in Biomedical Engineering." This themed section explores the integration of biomedical engineering and artificial intelligence (AI), focusing...